OncoMatch/Clinical Trials/NCT07001540
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Is NCT07001540 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx) for diffuse large b-cell lymphoma.
Treatment: Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx) — This is a prospective, multicenter, single-arm clinical study designed to evaluate the efficacy and safety of Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) patients ineligible for autologous transplantation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD79B overexpression
CD79b-positive DLBCL confirmed by pathology
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-cd20 monoclonal antibody — first-line
Must have received: anthracycline — first-line
Cannot have received: oxaliplatin
Cannot have received: gemcitabine
Lab requirements
Blood counts
absolute granulocyte count ≥ 1,000/mm3, platelet count ≥ 75,000/mm3
Kidney function
creatinine clearance > 30 mL/min, creatinine ≤1.5× ULN
Liver function
ALT/AST < 3x ULN and total bilirubin ≤1.5× ULN (< 5x ULN in patients with Gilbert syndrome, cholestasis due to hilar compression adenopathy, biliary obstruction due to liver involvement or lymphoma)
Cardiac function
no obvious cardiac insufficiency or cardiovascular disease
Hematological function: absolute granulocyte count ≥ 1,000/mm3, platelet count ≥ 75,000/mm3; Liver function: ALT/AST < 3x ULN and total bilirubin ≤1.5× ULN (< 5x ULN in patients with Gilbert syndrome, cholestasis due to hilar compression adenopathy, biliary obstruction due to liver involvement or lymphoma); Renal function: creatinine clearance > 30 mL/min, creatinine ≤1.5× ULN Lung function: indoor oxygen saturation ≥95%; Cardiac function: no obvious cardiac insufficiency or cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07001540 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior oxaliplatin, gemcitabine disqualifies patients from enrollment.
Does this trial require CD79B?
Yes, CD79B overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify